Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma?

2002 ◽  
Vol 57 (1) ◽  
pp. 117-124 ◽  
Author(s):  
Jeroen Schaap ◽  
Carmen F. A. Eustatia-Rutten ◽  
Marcel Stokkel ◽  
Thera P. Links ◽  
Michaela Diamant ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Radioiodine Therapy ◽  
Differentiated Thyroid Carcinoma

Evaluation of Parotid Salivary Gland Echo Texture by Ultrasound Examinations and Correlation With Whole‐Body Scintigraphy After Radioiodine Therapy in Patients With Differentiated Thyroid Carcinoma

2020 ◽  
Vol 39 (9) ◽  
pp. 1811-1818
Author(s):  
Graziele Aparecida Simões Lima ◽  
Rossana Verónica Mendoza López ◽  
Ricardo Miguel Costa Freitas ◽  
Jose Willegaignon ◽  
Marcelo Tatit Sapienza ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Thyroid Carcinoma ◽  
Radioiodine Therapy ◽  
Differentiated Thyroid Carcinoma ◽  
Whole Body ◽  
Parotid Salivary Gland

scholarly journals Recombinant Human Thyrotropin-Aided Radioiodine Therapy in Patients with Metastatic Differentiated Thyroid Carcinoma

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Ivana Zagar ◽  
Andreja A. Schwarzbartl-Pevec ◽  
Barbara Vidergar-Kralj ◽  
Rika Horvat ◽  
Nikola Besic
Keyword(s):  
Thyroid Carcinoma ◽  
Total Thyroidectomy ◽  
Physical Condition ◽  
Radioiodine Therapy ◽  
Differentiated Thyroid Carcinoma ◽  
Therapeutic Benefit ◽  
The Poor ◽  
Radioiodine Ablation ◽  
Recombinant Human Thyrotropin ◽  
Tsh Stimulation

Our aim was to test the efficacy of 131-I therapy (RIT) using recombinant human TSH (rhTSH) in patients with differentiated thyroid carcinoma (DTC) in whom endogenous TSH stimulation was not an option due to the poor patient's physical condition or due to the disease progression during L-thyroxin withdrawal. The study comprised 18 patients, who already have undergone total or near-total thyroidectomy and radioiodine ablation and 0–12 (median 5) RITs after L-thyroxin withdrawal. Our patients received altogether 44 RITs using rhTSH while on L-thyroxin. Six to 12 months after the first rhTSH-aided RIT, PR and SD was achieved in 3/18 (17%) and 4/18 patients (22%), respectively. In most patients (n= 12; 61%) disease progressed despite rhTSH-aided RITs. As a conclusion, rhTSH-aided RIT proved to add some therapeutic benefit in 39% our patients with metastatic DTC, who otherwise could not be efficiently treated with RIT.

Incremental Diagnostic Value of SPECT/CT with131I Scintigraphy after Radioiodine Therapy in Patients with Well-differentiated Thyroid Carcinoma

Radiology ◽  
2012 ◽  
Vol 265 (3) ◽  
pp. 902-909 ◽  
Author(s):  
Yasuhiro Maruoka ◽  
Koichiro Abe ◽  
Shingo Baba ◽  
Takuro Isoda ◽  
Hirofumi Sawamoto ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Radioiodine Therapy ◽  
Diagnostic Value ◽  
Differentiated Thyroid Carcinoma ◽  
Well Differentiated

Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies

2006 ◽  
Vol 64 (6) ◽  
pp. 617-624 ◽  
Author(s):  
Y.Y. Liu ◽  
G. van der Pluijm ◽  
M. Karperien ◽  
M. P. M. Stokkel ◽  
A. M. Pereira ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Radioiodine Therapy ◽  
Differentiated Thyroid Carcinoma ◽  
In Vitro Studies
Sign in / Sign up

Export Citation Format

Share Document